Major CRO player Pharmaceutical Product Development (PPD) has won a lucrative seven-year government contract in infectious disease.
The pact, financials details of which were not revealed, falls under the Clinical Research Support Services program of the Division of AIDS, National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health.
Under the contract, PPD said it will “provide a broad range of clinical and other related research support services for the NIAID/DAIDS-supported clinical research portfolio and other infectious diseases relevant to HIV-infected and at-risk populations.”
“We are pleased to help NIAID develop and maintain a strong clinical infrastructure to meet the needs of DAIDS’ scientific agenda,” said William Sharbaugh, COO of the company.
RELATED: PPD to run first-in-human trial of Treos’ lead cancer vaccine
This latest agreement complements a long-standing collaboration between PPD and NIAID that, in March, was boosted to the middle of next decade, with PPD working on a "broad scope of research" in HIV.